Moreover, adagrasib (MRTX849) is a specifically optimized oral inhibitor of KRAS G12C mutant (69) by irreversibly and selectively binding to KRAS G12C in the inactive state, preventing it from sending cell growth signals and causing cancer cell death (70). Here, KRAS is linked to cancer.